CCR7 and breast carcinoma: Collectively, these results add newer insights into the multifaceted role played by the CCL21/CCR7 chemokine pair in mammary malignancy, prompting for the first time towards the involvement of this chemokine axis in the complex mechanics of breast cancer-induced lymphangiogenesis The proven therapeutic effectiveness of blocking CCR7-mediated CCL21 signaling [61] combined with the promising outlook [62] of phase 1 DC-CCL21 trial in lung cancer and melanoma patients [63], suggests that the inherent value of the present study is more than apparent.